Completely acquired Tanabe Pharma Factory Co., Ltd. as a subsidiary and inherited 17 components and 35 products in its manufacturing and marketing approvals. The acquired shares are 22,602 shares (100%), with transfer planned for late November 2026 and succession of approvals scheduled for April 2027 onward. Future production capacity aims to reach over 30 billion tablets in FY2036.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Toa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4553-20260703-01.pdf","jir_short_summary":"Completely acquired Tanabe Pharma Factory Co., Ltd. as a subsidiary and inherited 17 components and 35 products in its manufacturing and marketing approvals. The acquired shares are 22,602 shares (100%), with transfer planned for late November 2026 and succession of approvals scheduled for April 2027 onward. Future production capacity aims to reach over 30 billion tablets in FY2036.","jir_summary":"### Section headline\nThe company will make Tanabe Pharma Factory a wholly owned subsidiary and succeed its manufacturing and marketing approvals to strengthen the domestic generic pharmaceutical supply security. Tanabe Pharma Factory possesses global-standard manufacturing and quality control systems; through the succession, product item consolidation and production efficiency improvements are targeted.\n\n### Section 2 headline\nThe share transfer will involve acquiring 22,602 shares (100%). The transfer is planned for late November 2026. The succession of manufacturing and marketing approvals is planned for April 2027 onward. Going forward, goodwill is expected to arise, and impacts will be disclosed as they are determined. The plan targets production capacity of 24 billion tablets in FY2030 and over 30 billion tablets in FY2036.","jir_financial_highlights":"Number of shares acquired: 22,602 shares (Unknown)\nAcquisition price: Unknown (Unknown)\nSuccession timing for manufacturing and marketing approvals: From April 2027 onward (17 components, 35 products) (Unknown)","jir_category":"","jir_hashtags":"#ToaPharmaceuticals, #TanabePharma, #CorporateCollaboration","jir_key_figures":"Number of shares acquired: 22,602 shares (voting rights: 22,602)\nAcquisition price: Unknown\nSuccession timing for manufacturing and marketing approvals: From April 2027 onward (17 components, 35 products)","jir_meta_title":"Toa Pharmaceuticals: Notice of Complete Subsidiary Acquisition of Tanabe Pharma Factory and Succession of Approvals | July 2026","jir_meta_description":"Toa Pharmaceuticals obtains Tanabe Pharma Factory's shares to form a wholly owned subsidiary. By succeeding the manufacturing and marketing approvals, the company aims to strengthen domestic supply capacity and expand future production. Succession is scheduled for transfer in November 2026 and approval succession from April 2027 onward.","jir_og_title":"Toa Pharmaceuticals: Complete Subsidiary Acquisition of Tanabe Pharma Factory and Succession of Approvals","jir_og_description":"Complete a subsidiary acquisition of Tanabe Pharma Factory and succeed manufacturing and marketing approvals. Publicizing plans and schedule for future production capacity expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-75755","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n